We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.23B
AUM Growth
+$5.22B
Cap. Flow
+$232M
Cap. Flow %
4.44%
Top 10 Hldgs %
34.65%
Holding
139
New
8
Increased
26
Reduced
20
Closed
24

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$97.9M
2
UNH icon
UnitedHealth
UNH
+$60M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$51.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$37.9M
5
THC icon
Tenet Healthcare
THC
+$26.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$94.8M
2
PFE icon
Pfizer
PFE
+$57.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$31M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$24.5M
5
VRNA
Verona Pharma
VRNA
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
26
Pfizer
PFE
$144B
$71.4M 1.37%
1,393,600
-1,205,400
-46% -$57.8M
ACET icon
27
Adicet Bio
ACET
$76.7M
$66.6M 1.27%
465,446
– –
EW icon
28
Edwards Lifesciences
EW
$48.4B
$64.2M 1.23%
860,500
-105,800
-11% -$8.15M
PCVX icon
29
Vaxcyte
PCVX
$7.76B
$61.5M 1.18%
1,283,126
+565,226
+79% +$22.2M
VECT
30
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$60.7M 1.16%
7,006,861
+533,300
+8% +$4.29M
PRLD icon
31
Prelude Therapeutics
PRLD
$368M
$60.6M 1.16%
10,039,691
– –
THC icon
32
Tenet Healthcare
THC
$22.2B
$59.5M 1.14%
1,220,300
+577,000
+90% +$26.7M
CRNX icon
33
Crinetics Pharmaceuticals
CRNX
$8.87B
$58.5M 1.12%
3,196,876
– –
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$58.2M 1.11%
1,283,692
-135,200
-10% -$8.75M
PMVP icon
35
PMV Pharmaceuticals
PMVP
$58.7M
$57.1M 1.09%
6,563,077
– –
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$53.2M 1.02%
2,029,300
– –
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
$52.8M 1.01%
360,457
– –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.7B
$51.1M 0.98%
2,006,500
– –
RPTX
39
DELISTED
Repare Therapeutics
RPTX
$48.9M 0.93%
3,322,488
– –
XTNT icon
40
Xtant Medical Holdings
XTNT
$57.7M
$48.3M 0.92%
73,114,592
– –
ETNB
41
DELISTED
89bio
ETNB
$46.6M 0.89%
3,658,869
– –
SIBN icon
42
SI-BONE Inc
SIBN
$801M
$45.8M 0.88%
3,368,000
– –
XENE icon
43
Xenon Pharmaceuticals
XENE
$6.25B
$45.3M 0.87%
1,149,100
+11,800
+1% +$430K
ACRS icon
44
Aclaris Therapeutics
ACRS
$723M
$43.4M 0.83%
2,758,434
– –
IRON icon
45
Disc Medicine
IRON
$2.83B
$43M 0.82%
2,160,941
+1,966,734
+1,013% +$97.9M
ABCL icon
46
AbCellera Biologics
ABCL
$1.68B
$42.4M 0.81%
4,180,768
– –
SCPH
47
DELISTED
scPharmaceuticals
SCPH
$39.9M 0.76%
5,559,528
+762,380
+16% +$4.66M
QURE icon
48
uniQure
QURE
$2.7B
$39.6M 0.76%
1,747,555
+150,555
+9% +$3.25M
BLU
49
DELISTED
BELLUS Health Inc.
BLU
$38.7M 0.74%
4,708,900
+74,000
+2% +$690K
JANX icon
50
Janux Therapeutics
JANX
$902M
$37.4M 0.71%
2,836,386
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2022 Portfolio in Review

As of Q4 2022, OrbiMed held 139 positions worth $5.23B, up 96,938% from $5.39M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $232M of net new capital in Q4 2022, opening 8 new positions and adding to 26 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $94.8M trimmed.

  • OrbiMed's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.
  • OrbiMed added most to Disc Medicine in Q4 2022, an estimated $97.9M increase.
  • OrbiMed's biggest Q4 2022 reduction was argenx, cutting an estimated $94.8M.
  • OrbiMed fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $108K.
  • OrbiMed's ten largest holdings make up 35% of its $5.23B portfolio in Q4 2022.
  • OrbiMed opened 8 new positions and closed 24 in Q4 2022.
  • OrbiMed's portfolio value rose 96,938% quarter-over-quarter to $5.23B.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.